The presence of latex in different components of pre-filled syringes or nasal applicators of three anti-influenza vaccines authorized for the 2019-2020 season cannot be excluded. This was revealed by the Italian drug agency, which conducted an in-depth study with companies. An "extremely important information for latex allergy sufferers who need vaccination coverage, which, in the presence of latex even in traces – says AIFA – would be exposed to the risk of allergic reactions". Such patients should consult a doctor.
The possible presence of traces of latex does not concern the vaccine but the external components or a possible contact during the production process. These are the vaccines concerned: company Mylan IRE HEALTHCARE LIMITED with the «Influvac S tetra» vaccine for which «it does not contain latex – it cannot be excluded the possibility that, during the production process, the vaccine came into contact with instruments containing latex . Latex-sensitive patients are advised to consult their doctor before administering the vaccine "; company Mylan Italia S.r.l. with the «Influvac S *» vaccine; the company Seqirus srl with the vaccines Agrippal S1, Fluad, Influpozzi subunit, Innoflu *, Flucelvax tetra. For these last vaccines "it cannot be excluded that the needle cover caps and the protective caps of the syringes do not contain latex".
«The notice published by Aifa concerns only the packaging of influenza vaccines to protect those who have allergies to this substance. This is to allow even allergy sufferers an adequate vaccination by informing them about latex-free products. No contamination therefore in the flu vaccines »Aifa specifies.
Therefore, Aifa recommends latex-sensitive patients to consult their doctor before the vaccine is given.
© REPRODUCTION RESERVED